Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 6:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2281–2304 of 13,471 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Endocrine Disorders Clear all

Conditions: Hereditary Thyroid Gland Medullary Carcinoma, Locally Advanced Thyroid Gland Medullary Carcinoma, Multiple Endocrine Neoplasia Type 2A, Multiple Endocrine Neoplasia Type 2B, Recurrent Thyroid Gland Medullary Carcinoma, Sporadic Thyroid Gland Medullary Carcinoma, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IV Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7
Interventions: Sorafenib Tosylate; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2022
U.S. locations: 3
States / cities: St Louis, Missouri • Durham, North Carolina • Columbus, Ohio

Conditions: Diabetes Mellitus, Type 2
Interventions: Placebo, PF-00734200 10 mg QD, PF-00734200 20 mg QD, PF-00734200 5 mg QD, PF-00734200 2 mg QD; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 303 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2008
U.S. locations: 64
States / cities: Birmingham, Alabama • Gilbert, Arizona • Phoenix, Arizona + 49 more

Conditions: Hypothyroidism; Surgery, Head and Neck Cancer, Wound Heal, Laryngeal Cancer, Laryngeal Fistula
Interventions: Levothyroxine; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Pancreas Cancer
Interventions: Secretin Synthetic Human (RG1068); Drug
Lead sponsor: University Hospitals Cleveland Medical Center; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2012
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Adult Growth Hormone Deficiency, Mild Traumatic Brain Injury
Interventions: Somatropin, Placebo; Drug · Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 21 Years to 55 Years
Enrollment: 172 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 16
States / cities: Birmingham, Alabama • Phoenix, Arizona • San Diego, California + 13 more

Conditions: Type 2 Diabetes
Interventions: Practice Facilitation; Behavioral
Lead sponsor: The University of Texas Health Science Center at San Antonio; Other
Eligibility: Not listed
Enrollment: 2,493 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Diabetes, Wound Infection, Healthy Volunteers
Interventions: Omadacycline, Microdialysis Catheter Insertion; Drug · Procedure
Lead sponsor: Hartford Hospital; Other
Eligibility: 18 Years and older
Enrollment: 14 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Hartford, Connecticut

Conditions: Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Polyneuropathy
Interventions: SB-509, Saline; Drug · Other
Lead sponsor: Sangamo Therapeutics; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 170 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2016
U.S. locations: 31
States / cities: Phoenix, Arizona • Scottsdale, Arizona • Tucson, Arizona + 28 more

Conditions: Painful Diabetic Neuropathy, Diabetes Mellitus
Interventions: Active: WST-057 4mL (146 mg pirenzepine free base monohydrate) topical solution, Placebo: WST-057 4mL topical solution; Drug
Lead sponsor: WinSanTor, Inc; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 58 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Diabetes Mellitus
Interventions: Exubera, Randomized diabetes therapy; Drug · Other
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 7,439 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 131
States / cities: Bay Minette, Alabama • Graysville, Alabama • Pell City, Alabama + 111 more

Conditions: Ovarian Cancer
Interventions: Doxil (Pegylated Liposomal Doxorubicin), BIBF 1120; Drug
Lead sponsor: Hoosier Cancer Research Network; Other
Eligibility: 18 Years and older · Female only
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Indianapolis, Indiana • Madison, Wisconsin

Conditions: Type 1 Diabetes Mellitus
Interventions: Decision Support System, Usual Care; Device · Other
Lead sponsor: Daniel Chernavvsky, MD; Other
Eligibility: 21 Years to 65 Years
Enrollment: 33 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Diabetes Mellitus in Pregnancy
Interventions: SweetMama Focus Groups, SweetMama Individual Testing, SweetMama Feasibility Testing - Pilot Randomized Trial; Behavioral
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 80 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma, Refractory Ovarian Carcinoma
Interventions: BET Bromodomain Inhibitor ZEN-3694, Biopsy Procedure, Biospecimen Collection, Computed Tomography, Ipilimumab, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, X-Ray Imaging; Drug · Procedure · Biological
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2028
U.S. locations: 9
States / cities: Bethesda, Maryland • New York, New York • The Bronx, New York + 3 more

Conditions: Myocardial Infarction, Diabetes Mellitus, Peripheral Arterial Disease
Interventions: Vorapaxar, Clopidogrel, Aspirin; Drug
Lead sponsor: University of Florida; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Jacksonville, Florida

Conditions: Pancreatic Carcinoma, Pancreatic Intraductal Papillary Mucinous Neoplasm, Pancreatobiliary-Type
Interventions: Optical Coherence Tomography, Therapeutic Conventional Surgery, Laboratory Evaluation; Procedure · Diagnostic Test
Lead sponsor: Ohio State University Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Type 2 Diabetes Mellitus, Myocardial Fibrosis, Myocardial Inflammation
Interventions: dapagliflozin, Placebo; Drug · Other
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Gestational Diabetes
Interventions: Dietary modification and medications; Behavioral
Lead sponsor: University of Pittsburgh; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 47 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: Diabetes, Liver Transplant; Complications, Kidney Transplant Failure
Interventions: hemoglobin A1c; Diagnostic Test
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Metastatic Invasive Breast Cancer, Resistant Breast Cancer, ER+, HER2-, Metastatic Breast Cancer
Interventions: Neratinib + endocrine therapy, Endocrine therapy may include one of the following therapies: letrozole, anastrozole, exemestane, tamoxifen or fulvestrant, CDK4/6 + Endocrine therapy; Drug
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years and older · Female only
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2035
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Type 1 Diabetes
Interventions: Transition preparation program, Educational materials; Behavioral · Other
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 16 Years and older
Enrollment: 109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Cardiovascular Diseases, Diabetes Mellitus, Hyperlipidemia, Hypertension, Obesity
Interventions: Nutritional counseling, Walking program, Simple pedometer, Enhanced pedometer; Behavioral · Device
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older · Male only
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2009
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Coronavirus Infection, Type 2 Diabetes
Interventions: Linagliptin, Insulin regimen; Drug
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Breast Cancer
Interventions: Endocrine Therapy and a CDK 4/6 inhibitor; Drug
Lead sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins; Other
Eligibility: 18 Years to 100 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Search by objective public record fields.

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

12 Week Study Of PF-00734200 For The Treatment Of Type 2 Diabetes Mellitus In Subjects Treated With Metformin

Wound Complications in Head and Neck Surgery

Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity

Growth Hormone Replacement Therapy in Veterans With Mild Traumatic Brain Injury (mTBI) and Adult Growth Hormone Deficiency (AGHD)

Improving Risk Factors for Diabetes Complications in Primary Care

Omadacycline Tissue Penetration in Diabetic Patients With Wound Infections and Healthy Volunteers Via In Vivo Microdialysis

Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy

A 12-Week Study of Topical Pirenzepine or Placebo in Type 2 Diabetic Patients (T2DM) With Painful Peripheral Neuropathy

Follow-Up Study for Exubera

Doxorubicin + BIBF 1120 in Patients for Ovarian Cancer

Feasibility of a Decision Support System to Reduce Glucose Variability in Subject With T1DM

SweetMama: Testing of a Novel Technology for Diabetes Education and Support to Pregnant Women

Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors

Vorapaxar as an Add-On Antiplatelet Therapy in Patients With and Without Diabetes Mellitus

Ultra-High Resolution Optical Coherence Tomography in Detecting Micrometer Sized Early Stage Pancreatic Cancer in Participants With Pancreatic Cancer

Effects of SGLT-2 Inhibition on Myocardial Fibrosis and Inflammation as Assessed by Cardiac MRI in Patients With DM2

Gestational Diabetes Diagnostic Methods

Optimal A1c Control in Post Liver or Combined Liver and Kidney Transplant Recipients Who Have Diabetes Mellitus

Neu Direction: Testing the Efficacy of Adding HER Inhibition to Standard of Care in Metastatic MLH1-low Endocrine-resistant ER+/HER2- Breast Cancer

Improving Transition Care for Adolescents and Young Adults With Type 1 Diabetes

Veterans Walk for Health Study

Effects of DPP4 Inhibition on COVID-19

Determinants of Resistance to Endocrine Therapy and a Cyclin-dependent Kinases 4 and 6 (CDK4/6) Inhibitor for HR+ MBC